1. United Kingdom Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Probiotix Health Plc

Probiotix Health Plc

AAQSE:PBX
8.93
GBX
+1.18
(+15.16%)
1.07BMarket Cap
Probiotix Health Plc
AQSE:PBX
(Aquis Stock Exchange)

Recent

price

8.93

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2022
2023
2024
2025
TTM
GBP
- -
- -
0.01
- -
0.01
0.01
0.02
- -
Revenue per Share
- -
- -
- -
- -
-0.01
-0.01
-0.01
- -
Basic EPS, GAAP
- -
- -
- -
-0.01
- -
-0.01
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
0.01
0.01
0.01
0.01
0.01
Book Value per Share
- -
-0.01
-0.01
0.01
0.01
0.01
0.01
0.01
Tangible Book Value per Share
122
122
122
90
122
133
158
158
Basic Weighted Avg Shares
- -
- -
1
- -
2
2
3
- -
Sales/Revenue/Turnover
- -
-117.94
5.62
- -
-42.98
-44.56
-45.31
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
-1
-1
-1
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-142.48
-1.62
- -
-44.65
-44.98
-45.13
- -
Profit Margin (%)
- -
- -
1
2
1
2
1
1
Working Capital
- -
1
1
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
2
2
2
1
1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
-45.36
-49.04
-73.26
- -
Return on Common Equity (%)

Capital Structure

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
158
158
158
Market Capitalization
9
10
11

Working Capital

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
2
2
2
Cash, Cash Equivalents & STI
2
1
1
Accounts Receivable, Net
- -
1
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
1
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-106.3%
-24.96%
Free Cash Flow
- -
331.26%
-64.58%
Net Income, GAAP
- -
- -
45.57%
Sales/Revenue/Turnover
- -
- -
45.09%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
2
2024
- -
- -
2
2025
- -
- -
3

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.01
2024
- -
- -
-0.01
2025
- -
- -
-0.01

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
ProBiotix Health Plc is a United Kingdom-based life sciences and biotechnology company that specializes in the development, formulation, and commercialization of clinically validated probiotic strains and microbiome-modulating ingredients for cardiovascular and metabolic health. Founded in 2021 as a spin-out from OptiBiotix Health plc and headquartered in Wakefield, United Kingdom, the company operates internationally across Europe, North America, the Asia-Pacific region, Latin America, and the Middle East. ProBiotix Health operates primarily within the nutraceutical, functional food, and pharmaceutical segments, serving global supplement brand owners, pharmaceutical distributors, healthcare organizations, and consumer markets. The company offers a systematic portfolio of products and commercial services, comprising proprietary active probiotic ingredients, anchored by its patented Lactobacillus plantarum LPLDL strain; branded finished dietary supplements under the CholBiome line, including CholBiome, CholBiomeX3, and CholBiomeBP; customized formulation, blending, and encapsulation services for third-party nutraceutical brands; bulk raw ingredient supply for integration into functional foods, dairy products, and beverages; and white-label manufacturing accompanied by clinical dossier support, intellectual property licensing, and regulatory compliance services. In recent developments, ProBiotix Health has significantly expanded its global commercial footprint by entering into multiple multi-year distribution and supply agreements across North America, Southeast Asia, and mainland Europe to broaden market penetration for its finished product portfolio. The company has also broadened its strategic partnerships with international pharmaceutical and healthcare corporations to co-develop LPLDL-powered cardiometabolic formulations, expanded manufacturing and supply chain partnerships to increase production capacity, and advanced research initiatives to support new health claims and therapeutic applications in lipid management and physiological wellness.